Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET

Company Participants

Christine Chiou - Senior Vice President-Investor Relations

Samantha Du - Founder, Chairperson & Chief Executive Officer

Josh Smiley - President & Chief Operating Officer

Rafael Amado - President & Head of Global Oncology and Research & Development

Harald Reinhart - President & Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

Yajing Chen - Chief Financial Officer

Conference Call Participants

Louise Chen - Cantor

Yigal Nochomovitz - Citigroup

Anupam Rama - JPMorgan

Ziyi Chen - Goldman Sachs

Operator

Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab's Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, today's conference is being recorded.

It is now my pleasure to turn the floor over to Christine Chiou, Senior Vice President of Investor Relations. Please go ahead.

Christine Chiou

Thank you, operator. Good morning, good evening, and welcome, to Zai Lab’s Third Quarter 2023 Earnings Call. Today’s call will be led by Dr. Samantha Du, Zai Lab’s Founder, CEO and Chairperson. She will be joined by Josh Smiley, President and Chief Operating Officer, Dr. Rafael Amado, President and Head of Global Oncology and Research and Development, Dr. Harald Reinhart, President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases and Dr. Yajing Chen, Chief Financial Officer. Jonathan Wang, our Chief Business Officer will also be available to answer questions during the Q&A portion of the call.

As a reminder, during today's call, we will all be making certain forward-looking statements based on their current expectations. These statements are subject to numerous risk and uncertainties that may cause actual results to differ materially from what we expect due to a variety of factors including those discussed in our SEC filings. We will also refer to product revenue growth rates on a constant exchange rate basis, which is a non-GAAP financial measure. Please refer to our earnings release furnished with the SEC on November 7, 2023 for certain disclosures regarding this non-GAAP financial measures.

At this time, it is my pleasure to turn the call over to Dr. Samantha Du.

Samantha Du

Thank you, Christine. Hello everyone, and thank you all for joining us today. Throughout the year, we have continued to successfully advance our pipeline, including several important developments for key late-stage programs, such as Bema, KarXT [Indiscernible] and Efgartigimod.